ITHACA, N.Y., August 1, 2018 — Advion, Inc., a leading systems and consumables provider for the life sciences industry, is pleased to announce the new location of the company headquarters within the Cornell Business and Technology Park at 61 Brown Rd., Suite 100, Ithaca, NY 14850. Sparked by growth in demand and the need for additional... Read more
NeoLSD™ MSMS Kit is First Commercial IVD Kit to Use Mass Spectrometry to Screen for Six LSDs in Newborn Babies from a Single Dried Blood Spot Sample WHAT: PerkinElmer, Inc., a global leader in innovating for a healthier world, today announced that it received 510(k) clearance from the FDA to commercially market its NeoLSD™ MSMS... Read more
Hilden, Germany, and Germantown, Maryland, July 30, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON-TB® Gold Plus (QFT-Plus), the gold standard in accurate, cost-effective testing for latent tuberculosis (TB) infection, has been adopted by the International Organization for Migration (IOM) for use in screening migrants for the infection. As the United... Read more
Assist in Screening and Diagnosing ANCA-Associated Vasculitis WALTHAM, Mass. – July 25, 2018 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its EUROIMMUN ANCA IFA and EUROPLUS Granulocyte Mosaic™ assays for use with EUROPattern microscope have received 510(k) clearance from the U.S. Food & Drug Administration (FDA).... Read more
Basel, 20 July 2018 FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.... Read more
Basel, 20 July 2018 FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.... Read more
Lagos, Nigeria – July 4, 2018: GE (NYSE: GE), the world’s premier digital industrial company and the Lagos State Government have agreed to pool their resources for the development of critical infrastructure in the state in the areas of Power, Healthcare and Skills Development. This was announced during the signing of a Support and Cooperation Agreement... Read more
Wednesday, July 18, 2018 Vienna, Austria – AMETEK Grabner Instruments and Agilent Technologies Inc. announce an OEM agreement for an innovative mobile testing solution for in-the-field analysis of lubricating oils and greases. Grabner Instruments, based in Austria, is well known for developing and manufacturing automatic petroleum testing equipment. In this partnership, Grabner will focus on lube... Read more
Agilent and Grabner Instruments Provide Innovative Mobile Testing Solution for the Petroleum Industry SANTA CLARA, Calif., July 18, 2018 Agilent Technologies Inc. (NYSE: A) announces an equipment manufacturing agreement with Grabner Instruments, a subsidiary of AMETEK, Inc. The agreement is focused on an innovative mobile testing solution for in-field analysis of lubricating oils and greases.... Read more
Basel, 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab)... Read more